S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.63 (+1.34%)
AAPL   122.79 (+3.14%)
MSFT   216.20 (+1.00%)
FB   286.76 (+3.53%)
GOOGL   1,795.71 (+2.35%)
AMZN   3,220.00 (+1.64%)
TSLA   585.07 (+3.08%)
NVDA   535.52 (-0.10%)
BABA   263.67 (+0.12%)
CGC   26.73 (-7.19%)
GE   10.15 (-0.29%)
MU   67.16 (+4.79%)
AMD   92.61 (-0.05%)
T   28.87 (+0.42%)
NIO   45.51 (-9.93%)
F   9.23 (+1.65%)
ACB   9.72 (-16.78%)
NFLX   504.39 (+2.79%)
BA   213.13 (+1.15%)
GILD   61.03 (+0.59%)
DIS   149.53 (+1.03%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.63 (+1.34%)
AAPL   122.79 (+3.14%)
MSFT   216.20 (+1.00%)
FB   286.76 (+3.53%)
GOOGL   1,795.71 (+2.35%)
AMZN   3,220.00 (+1.64%)
TSLA   585.07 (+3.08%)
NVDA   535.52 (-0.10%)
BABA   263.67 (+0.12%)
CGC   26.73 (-7.19%)
GE   10.15 (-0.29%)
MU   67.16 (+4.79%)
AMD   92.61 (-0.05%)
T   28.87 (+0.42%)
NIO   45.51 (-9.93%)
F   9.23 (+1.65%)
ACB   9.72 (-16.78%)
NFLX   504.39 (+2.79%)
BA   213.13 (+1.15%)
GILD   61.03 (+0.59%)
DIS   149.53 (+1.03%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.63 (+1.34%)
AAPL   122.79 (+3.14%)
MSFT   216.20 (+1.00%)
FB   286.76 (+3.53%)
GOOGL   1,795.71 (+2.35%)
AMZN   3,220.00 (+1.64%)
TSLA   585.07 (+3.08%)
NVDA   535.52 (-0.10%)
BABA   263.67 (+0.12%)
CGC   26.73 (-7.19%)
GE   10.15 (-0.29%)
MU   67.16 (+4.79%)
AMD   92.61 (-0.05%)
T   28.87 (+0.42%)
NIO   45.51 (-9.93%)
F   9.23 (+1.65%)
ACB   9.72 (-16.78%)
NFLX   504.39 (+2.79%)
BA   213.13 (+1.15%)
GILD   61.03 (+0.59%)
DIS   149.53 (+1.03%)
S&P 500   3,662.45 (+1.13%)
DOW   29,823.92 (+0.63%)
QQQ   303.63 (+1.34%)
AAPL   122.79 (+3.14%)
MSFT   216.20 (+1.00%)
FB   286.76 (+3.53%)
GOOGL   1,795.71 (+2.35%)
AMZN   3,220.00 (+1.64%)
TSLA   585.07 (+3.08%)
NVDA   535.52 (-0.10%)
BABA   263.67 (+0.12%)
CGC   26.73 (-7.19%)
GE   10.15 (-0.29%)
MU   67.16 (+4.79%)
AMD   92.61 (-0.05%)
T   28.87 (+0.42%)
NIO   45.51 (-9.93%)
F   9.23 (+1.65%)
ACB   9.72 (-16.78%)
NFLX   504.39 (+2.79%)
BA   213.13 (+1.15%)
GILD   61.03 (+0.59%)
DIS   149.53 (+1.03%)
Log in
NASDAQ:XBIT

XBiotech Stock Forecast, Price & News

$18.92
-0.14 (-0.73 %)
(As of 12/1/2020 03:57 PM ET)
Add
Compare
Today's Range
$18.85
Now: $18.92▼
$19.39
50-Day Range
$16.78
MA: $18.65▼
$19.92
52-Week Range
$8.72
Now: $18.92▼
$26.40
Volume1,187 shs
Average Volume366,462 shs
Market Capitalization$553.62 million
P/E Ratio1.31
Dividend YieldN/A
Beta1.5
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. Its product candidates include 514G3, an anti-infective antibody that is in Phase II clinical trial for the treatment of Staphylococcus Aureus infections; and other anti-infectious disease antibodies, which are in pre-clinical development to treat Clostridium Difficile, influenza, Ebola, and Herpes Varicella Zoster (Chickenpox). XBiotech Inc. has a collaboration with BioBridge Global for the development of potential COVID 19 treatment based on natural antibodies from recovered patients. The company was founded in 2005 and is headquartered in Austin, Texas.
XBiotech logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.39 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:XBIT
Previous Symbol
CUSIPN/A
CIK1626878
Webwww.xbiotech.com
Phone512-386-2900
Employees78

Debt

Debt-to-Equity RatioN/A
Current Ratio18.28
Quick Ratio18.28

Price-To-Earnings

Trailing P/E Ratio1.31
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$18.20 per share
Price / Book1.04

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$668.63 million
Net MarginsN/A
Return on Equity-7.07%
Return on Assets-6.67%

Miscellaneous

Outstanding Shares29,261,000
Market Cap$553.62 million
Next Earnings Date3/15/2021 (Estimated)
OptionableOptionable
$18.92
-0.14 (-0.73 %)
(As of 12/1/2020 03:57 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XBIT News and Ratings via Email

Sign-up to receive the latest news and ratings for XBIT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











XBiotech (NASDAQ:XBIT) Frequently Asked Questions

How has XBiotech's stock price been impacted by COVID-19 (Coronavirus)?

XBiotech's stock was trading at $10.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, XBIT shares have increased by 78.5% and is now trading at $19.13.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of XBiotech?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for XBiotech or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than XBiotech?

Wall Street analysts have given XBiotech a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but XBiotech wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is XBiotech's next earnings date?

XBiotech is scheduled to release its next quarterly earnings announcement on Monday, March 15th 2021.
View our earnings forecast for XBiotech.

What price target have analysts set for XBIT?

2 Wall Street analysts have issued 1-year price objectives for XBiotech's stock. Their forecasts range from $18.00 to $28.00. On average, they anticipate XBiotech's share price to reach $23.00 in the next year. This suggests a possible upside of 20.2% from the stock's current price.
View analysts' price targets for XBiotech.

Who are some of XBiotech's key competitors?

Some companies that are related to XBiotech include uniQure (QURE), I-Mab (IMAB), Viela Bio (VIE), Zentalis Pharmaceuticals (ZNTL), Y-mAbs Therapeutics (YMAB), Intra-Cellular Therapies (ITCI), Kura Oncology (KURA), Trillium Therapeutics (TRIL), IGM Biosciences (IGMS), Myovant Sciences (MYOV), Amarin (AMRN), Cryoport (CYRX), Aurinia Pharmaceuticals (AUPH), Dicerna Pharmaceuticals (DRNA) and Kronos Bio (KRON).
View all competitors.

What other stocks do shareholders of XBiotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), The Walt Disney (DIS), Cisco Systems (CSCO), NVIDIA (NVDA), Inovio Pharmaceuticals (INO), Intel (INTC), Pfizer (PFE) and Square (SQ).

Who are XBiotech's key executives?

XBiotech's management team includes the following people:
  • Mr. John Simard, Founder, Pres, CEO & Chairman (Age 58, Pay $827.87k)
  • Ms. Queena Han B.A., CPA, C.G.A., VP of Fin. & HR and Sec. (Age 53, Pay $408.97k)
  • Dr. Sushma Shivaswamy, Chief Scientific Officer (Age 42, Pay $606.24k)
  • Ms. Lisa Simard, Director of Corp. Strategy - XBiotech USA, Inc.
  • Mr. Benjamín Guzmán, Sr. VP of Corp. Strategy & Fin. (Age 64)

When did XBiotech IPO?

(XBIT) raised $76 million in an initial public offering on Wednesday, April 15th 2015. The company issued 4,000,000 shares at $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

What is XBiotech's stock symbol?

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

Who are XBiotech's major shareholders?

XBiotech's stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.43%), State Street Corp (0.94%), Wells Fargo & Company MN (0.25%), AQR Capital Management LLC (0.22%), Alps Advisors Inc. (0.13%) and Alps Advisors Inc. (0.13%). Company insiders that own XBiotech stock include Fondation Rennes, Queena Han, Street Financial SA Bay, Sushma Shivaswamy, W Thorpe Mckenzie and W Thorpe Mckenzie.
View institutional ownership trends for XBiotech.

Which institutional investors are selling XBiotech stock?

XBIT stock was sold by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, BlackRock Inc., AQR Capital Management LLC, Aperio Group LLC, Virginia Retirement Systems ET AL, Virtus ETF Advisers LLC, State Street Corp, and Alps Advisors Inc.. Company insiders that have sold XBiotech company stock in the last year include Queena Han, Street Financial SA Bay, Sushma Shivaswamy, and W Thorpe Mckenzie.
View insider buying and selling activity for XBiotech.

Which institutional investors are buying XBiotech stock?

XBIT stock was acquired by a variety of institutional investors in the last quarter, including Vestcor Inc, Wells Fargo & Company MN, DekaBank Deutsche Girozentrale, BNP Paribas Arbitrage SA, WINTON GROUP Ltd, California State Teachers Retirement System, and California Public Employees Retirement System. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes, and W Thorpe Mckenzie.
View insider buying and selling activity for XBiotech.

How do I buy shares of XBiotech?

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is XBiotech's stock price today?

One share of XBIT stock can currently be purchased for approximately $19.13.

How big of a company is XBiotech?

XBiotech has a market capitalization of $559.76 million. XBiotech employs 78 workers across the globe.

What is XBiotech's official website?

The official website for XBiotech is www.xbiotech.com.

How can I contact XBiotech?

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]

This page was last updated on 12/1/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.